- P-ISSN 1010-0695
- E-ISSN 2288-3339
Objective:The purpose of experimental study was to prove the effects of Boyangmakseong-bang (BYMSB) treatment on cBSA-induced in a MN mouse model. Methods:We divided mice into 4 groups. The Normal group had no treatment. We used cBSA and induced MN mouse model to the other 3 groups. The Control group was treated with cBSA (9㎎/㎏ i.p) only. The second group, named ‘BY-250’, was treated with cBSA (9㎎/㎏ i.p) and BYMSB extract (250㎎/㎏, p.o). The third group, named ‘BY-500’, was treated with cBSA (9㎎/㎏ i.p) and BYMSB extract (500㎎/㎏, p.o). After cBSA and BYMSB extract treatment for 4 weeks, the increase in percentage of body weight, proteinuria, serum albumin, total cholesterol, creatinine and BUN of all groups were measured. The CD3+, CD19+, CD4+, CD8+ cell levels of spleen of all groups were analyzed. IgA, IgG, IgM, IL-1β, TNF-α, IL-6 and IFN-γ levels of all groups were gauged. H&E staining, immunofluorescence staining and electron microscopy of kidney were observed. Results:BYMSB showed significant decrease in the 24hrs proteinuria, serum total cholesterol, serum IgG levels and BUN levels, and showed significant increase in the serum albumin levels compared with the control group. BYMSB showed increase in the increasing percentage of body weight and IFN-γ levels compared with the control. BYMSB showed decrease in the CD3+ T cells, CD4+ Th cells, IL-1β, TNF-α and IL-6 levels, but did not show significant change compared with the control. BYMSB showed considerable decrease in the thickening of the GBM on H&E staining, deposition of IgG on immunofluorescence staining and deposition of electron-density on electron microscopy of kidney compared with the control. Conclusions:According to the above results, it is suggested that BYMSB decreases the symptoms of MN induced by cBSA in a mouse model. Therefore BYMSB seems to be applicable to MN in clinical practice.
1 Yang J.O., Lee S.J., Park G.H., Chang Y.K., Lee K.W., Suh K.S., Shin Y.T., A Clinical and Pathological Study of Adult Membranous Nephropathy. The Korean Journal of Nephrology. 2001;28(2):263-76.
2 杜鋪京. 東醫腎系學. 서울:東洋醫學硏究院卅版部; 1993. p.89, 238-42, 301, 305,369-78, 393-6, 842, 852, 855, 915.
3 杜鋪京. 臨床野系早研究. 서울:成輔社; 1995, p.12, 244-8, 252, 280, 281
4 Lee BH, Cho HY, Kang HG, Ha IS, Cheong HI, Moon KC. Idiopathic membranous nephropathy in children. Pediatr Nephrol. 2006;21(11): 1707-15.
5 Ferrario F, Rastadi MP. Histopathological atlas of renal diseases: membranous giomeruionephritis. J Nephrol. 2004;17(5):635-6.
6 Passos EM, Legallicier B, Godin M. Membranous nephropathy. Rev Prat. 2003;53(18):2033-8.
7 Ronco P, Debiec H. New insights into the pathogenesis of membranous glomeruionephritis. Curr Opin Nephrol Hypertens. 2006; 15(3)258-63.
8 이종호, 김윤구, 한진석, 김성권, 이정상. 원발성 막성 신병증의 임상 및 병리학적 고찰. 대한신장학회지. 1987;6(1):219-20.
9 Kook Hwan Oh, Cu Rie Ahn, Jae Suk Yamg, Dae Teon Hwang, Jin suk Han, Hyeon Sun Lee. Clinicopathological Study on Adult Nephrotic Syndrome. The Korean Journal of Nephrology. 1995;14(2):254-65.
10 Kyu Hun Choi. Membranous. The Korean Journal of Nephrology. 1996;15(2):S-106-112.
11 대한신장학회. 임상신장학. 서울: 광문출판사;2001, p.246.
12 대한병리학회, 병리학. 서울 : 고문사;2004, p.676.
13 연세대학교 신장질환연구소. 신장학, 서울: 의학문화서; 1999, p.488, 491-3
14 서울대학교 의과대학. 신장학. 서울:서울대학교 출판부; 1998, p.158-191.
15 전국의과대학교수 역. 오늘의 진단 및 치료. 서울 : 도서출판 한우리; 1999, p.983.
16 Goumenos DS, Ahuja M, Davlouros P, El Nahas AM, Brown CB. Prednisolone and azathioprine in membranous nephropathy: a 10-yaer followup study. Clin Nephrol. 2006;65(5):317-23.
17 du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis. 2005;46(6):1012-29.
18 Durkan A, Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. 2005;18(2):CD002290.
19 이기태, 박경대, 황은아, 박성배, 김현철. 특발성 막성신염의 장기 성적. 대한신장학회 춘계학술대회초록집. 1999:199.
20 K.W. Lee, K.T. Bin, S.S Kim, Y.T Shin. Immunosuppressive Treatment of Adult Menbranous Nephropathy. The Korean Journal of Nephrology. 1995;14(3):293-302.
21 Hyun Phil Shin, Sang Ho Lee, Tae Won Lee, Myung Jae Kim, Chun Gyoo Ihm. Treatment outcomes and predictors in patients with idiopathic membranous nephropathy. The Journal of Korean Oriental Internal Medicine. 2004;66(3):267-73.
22 Seol Yong Yoon, Eun Ju Lee, Jung Hoon Huh, Young Ki Son, Kyoung Kun Han, Won Suk An. Clinical courses of the adult patients with idiopathic membranous nephropathy. Korean Journal of Medicine. 2004;66(2):175-85.
23 張大寧. 實用中醫腎病學. 北京:中國醫藥科技卅 版社; 1990, p.90-6, 344-6.
24 白雲貞, 陳主康. 膜性腎病的中醫臨床與實驗研究 進展. 天津巾醫雜誌. 2001;18(2):53
25 張介賓. 景岳全書(下). 서울: 대성문화사; 1992, p. 460-1.
26 的天法, 抗行. 巾暫臨床腎臟病早. 上海:上海科學 技術文獻出版社; 1997, p.186-90
27 陳以平, 唐利群, 胡仲儀. 益氣活血係列均對IE件 腎炎模型基底膜影響的實驗研究. 中國中卅醫結 合雜誌. 1999; 19(2):96-9.
28 Kim Jae-Hyeong, Cho Chung-Sik, Kim Cheol- Jung, A Study for Effects of Magsungsinyeombang( Moxingshenyanfang) on Membranous Nephropathy induced by Cationic Bovine Serum Albuminin in Mouse Model(Effects of Magsungsinyeom- bang on Membranous Nephropathy). Journal of Meridian & Acupoint. 2007;24(4): 163-180.
29 Choi In-Gu, Cho Chung-Sik, Kim Cheol-Jung, A Study on the Effects of Chungyeolmaksungbang on Mouse Model of Membranous Nephropathy Induced by Cationic Bovine Serum Albumin. The Journal of Korean Oriental Internal Medicine. 2008;29(1):104-116.
30 Kim, Doo-Hee, Cho Chung-Sik, Kim Cheol-Jung. The Effects of Hwalhyulmaksung-bang (Huoxiemoxing- fang) on Membranous Nephropathy Induced by Cationic Bovine Serum Albumin in Mouse Model. J. of Korean Oriental Med. 2008; 29(4):68-82
31 이석재. <醫學人門. 臟冊條分 > 中 腎臟에 작용하는 藥物에 관한 研究 . 원광대학교 석사학위논문. 2006.
32 Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce, IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005;68(1)302-10.
33 Song Y, Ma J, Li CL. Mechanical research on effects of yishenqing on membranous nephropathy. Zhongguo Zhong Yao Za Zhi. 2002; 27(7):537 -40.
34 Nash AS, Mohammed NA, Wright NG. Experimental immune complex glomerulonephritis and nephrotic syndrome in cats immunised with cationised bovine serum albumin. Res Vet Sci. 1990; 49(3) :370-2.
35 al-Nawab MD, Bass Ps, Das AK, Davies DR. Immunoelectron microscopy of cationized bovine serum albumin-induced glomerulonephritis in the rabbit. J Pathol. 1992;167:33-40.
36 Rafati AA, Gharibi H, Iloukhani H. Conformational stability of bovine serum albumin by cationic surfactant treatments. Physics and Chemistry of Liquids. 2003;41:509-17.
37 Breysse P, Couser WG, Alpers CE, Nelson K, Gaur L, Johnson RJ. Membranous nephropathy and formaldehyde exposure. Ann Intern Med. 1994;120:396-7.
38 Chen JS, Chen A, Chang LC, Chang WS, Lee HS, Lin SH et al. Mouse model of membranous nephropathy induced by cationic bovine aibumin: antigen dose-response relations and strain differences. Nephrol Dial Transplant. 2004(19)11:2721-8.
39 Ghitescu L, Desjardins M, Bendayan M. Immunocytochemical study of glomerular permeability to anionic. neutral and cationic albumins. Kidney Int. 1993;42(1):25-32.
40 Barbara Y. John W. H. 기능적 관점에서 본 조직학. 서울: 범문사; 2004, p.216, 294
41 이귀녕. 임상병리파일. 서울:醫學文化社; 2000.pp.305-6
42 강성귀. 신장학. 서울:고려의학;1994, p.169-78.
43 라신택. 신장학. 서울: 의학문화사; 1999, p.501-5.
44 강재성 외. 세포분자면역학. 서울: 범문사; 2004, p. 480, 487, 497.
45 이중달. 그림으로 설명한 병리학. 서울: 고려의학; 1991. p.97-124.
46 신곡태. Pathophysiology로 이해하는 내과학. part7. 면역알레르기 질환. 서울:도서출판 정담; 2002. p.5, 11,69.
47 Yokoyama H, Yoshimoto K, Wada T. Membranous nephropathy. Nippon Rinsho. 2004;62(10) :1856-60.
48 Sementilli A, Moura LA, Franco MF. The role of electron micro- scopy for the diagnosis of glomerulopathies. 2004;122(3):104-9.
49 Passerini P. Treatment for idiopathic membranous nephropathy. G Ital Nefrol. 2004;21(6):531-9.